succinate dehydrogenase complex subunit D pseudogene 6Genealiases: []
Q-omics provides the consensus-scored SDHDP6 profile across patient tissues and cancer cell-line models. SDHDP6 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SDHDP6 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, SDHDP6 RNA expression shows 15,007 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BRCA, and UVM as cancer lineages where SDHDP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDHDP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDHDP6 survival associations across molecular data types. SDHDP6 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDHDP6 RNA expression–survival associations across cancer types. High SDHDP6 expression shows unfavorable associations in ACC, KIRP, COAD, UVM and GBM, but favorable associations in READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify ACC as the clearest survival context for SDHDP6 RNA expression.
This table summarizes SDHDP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SDHDP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDHDP6 shows lower tumor expression in BRCA, KICH, UCEC and LUAD. The BRCA box plot shows higher SDHDP6 RNA expression in normal versus tumor tissue (log2 FC = −0.648, t-test p < 0.001).
This table shows molecular features associated with SDHDP6 in patient tissues and cancer cell lines. In patient samples, SDHDP6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
